The aim of the study is to assess the short-term benefit of the combination of basiliximab, EC-MPS and cyclosporine microemulsion with C2 monitoring on the prophylaxis of acute rejection in a population of de novo renal transplant patients at potential high risk of DGF.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
46
Incidence of first episodes of BPAR at month 3 post transplant
Incidence of patients death at month 3 post transplant.
Incidence of graft loss or, synonymously, graft failure)
The allograft will defined as lost (or: to have failed)
when the patient begins dialysis treatments without
subsequent graft recovery.
The time of graft failure will be defined as the time of start of dialysis, or time of nephrectomy, whatever occurs first.
Number of myfortic dose adjustments/discontinuations
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.